back to search abstracts online

Monday February 1,1999	Tuesday February 2, 1999	Wednesday February 3,1999	Thursday February 4,1999
The Impact of HIV Infection on the Number of Recent Thymic Emigrants in Blood and the Effect of HAART. Quantifying Recent Thymic Emigrants (RTE) in Blood of 400 Normal Persons with a Real-Time PCR/ Molecular Beacon Assay for T-Cell Receptor (TCR) Excisional Circles (TREC). Potent and Aberrant CD4 Responses in Lymphoid Tissue (LT) during Primary HIV-1 Infection (PHI). Defect in Cytolytic Effector Molecules in Lymphoid Tissue (LT) during Primary HIV-1 Infection (PHI) is a Very Early Mechanism of Immune Dysfunction. Sexual Transmission and Propagation of SIV and HIV-1 in Activated and Quiescent T Cells Intermittent Drug Therapy Increases the Time to HIV Rebound in Humans and Induces the Control of SIV after Treatment Interruption in Monkeys. OKT3 and rhIL-2 in HIV-1 Patients on HAART with Prolonged Suppression of Plasma Viremia. Discontinuation of PCP prophylaxis (PRO) is safe in HIV-infected patients (PTS) with immunological recovery with HAART. Preliminary results of an open, radomised and multicentric clinical trial (GESIDA04/98). A Pilot Study of the Short-Term Effects of Antiretroviral Management Based on Plasma Genotypic Antiretroviral Resistance Testing (GART) in Patients Failing Antiretroviral Therapy. High Frequency of Antiretroviral Drug Resistance in HIV-1 from Recently Infected Therapy Naive Individuals The Spectrum and Frequency of Reduced Antiretroviral Drug Susceptibility With Primary HIV Infection in the United States. Selection of Protease Resistance Mutations in Semen. Viral rebound in the presence of indinavir without protease inhibitor resistance. Safety, Pharmacokinetics, and Antiviral Activity of T-20 as a Single Agent in Heavily Pre-treated Patients A Multi-Center, Randomized, Open-Label, Comparative Trial of the Clinical Benefit of Switching the Protease Inhibitor (PI) by Nevirapine (NVP) in HAART-Experienced Patients Suffering Lipodystrophy (LD) Randomized Trial of Abacavir (ABC) in Combination with Indinavir (IDV) and Efavirenz (EFV) in HIV-infected Patients (Pts) with Nucleoside Analog Experience (NRTI exp). A Phase III, Multicenter, Randomized, Open-Label Study to Compare the Antiretroviral Activity and Tolerability of Efavirenz (EFV) + Indinavir (IDV), versus EFV + Zidovudine (ZDV) + Lamivudine (3TC), versus IDV + ZDV + 3TC at 48 Weeks (Study DMP 266-006)